
|Videos|December 4, 2017
The Role of JAK2 Inhibition in Patients With PV
Author(s)John Mascarenhas, MD
John Mascarenhas, MD, associate professor, Icahn School of Medicine at Mount Sinai, discusses the role of <em>JAK2</em> inhibition in patients with polycythemia vera (PV).
Advertisement
John Mascarenhas, MD, associate professor, Icahn School of Medicine at Mount Sinai, discusses the role ofJAK2
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
4
First Patient Is Dosed in Trial of HLX-4310 for Relapsed/Refractory Osteosarcoma
5





























